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sCigarette  smoke  contains  a  mixture  of  over  5000  chemicals
many  of  which  harm  the  human  body  causing  a  broad  range
of  diseases.  With  approximately  5  million  tobacco-related
deaths  annually,  smoking  is  the  leading  cause  of  preventable
premature  mortality  in  the  world.1 Death  is  mainly  caused
by  lung  cancer,  ischemic  heart  disease,  chronic  obstructive
pulmonary  disease,  and  stroke.2,3
Tobacco  is  one  of  the  most  main  causes  of  respiratory
diseases.4
Smoking  is  also  recognized  as  a  risk  factor  for  inter-
stitial  lung  disease  (ILD).  The  relationship  of  smoking
with  each  of  these  entities  has  generally  been  established
on  the  basis  of  epidemiologic  evidence.5 The  relation-
ship  between  cigarette  smoking  and  pulmonary  Langerhans
cell  histiocytosis  (PLCH),  respiratory  bronchiolitis  (RB),
respiratory  bronchiolitis-associated  interstitial  lung  dis-
ease  (RB-ILD),  and  desquamative  interstitial  pneumonia
(DIP)  is  well  described.6--9 Data  suggesting  an  association
between  cigarette  smoking  and  acute  eosinophilic  pneu-
monia  (AEP)  are  also  emerging,  whereas  the  relationship
between  smoking  and  idiopathic  pulmonary  ﬁbrosis  and  non-
speciﬁc  interstitial  pneumonia  remains  uncertain.10,11
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ase,  stroke,  and  other  cancers  diminishes  rapidly  after
uitting.12
Smoking  cessation  maybe  the  most  important  and
ost-effective  therapeutic  option7 for  smoker  with  smoking-
elated  ILDs.  Smoking  cessation  should  be  strongly  encour-
ged  in  these  patients,  and  they  should  be  offered  effective
reatment.4
All  physicians  should  strongly  advise  every  patient  who
mokes  to  quit  because  evidence  shows  that  physician  advice
o  quit  smoking  increases  abstinence  rates.13 Evidence-
ased  recommendations  indicate  that  smoking  cessation
rograms  are  useful  in  helping  smokers  to  quit,13 but  the
owerful  addictive  qualities  of  nicotine  create  a  huge  hur-
le,  even  for  those  with  a  strong  desire  to  quit.  Once
stablished,  smoking  is  a  very  difﬁcult  addiction  to  break.
The  majority  of  smokers  persist  in  tobacco  use  for  many
ears  and  typically  cycle  through  multiple  periods  of  remis-
ion  and  relapse.  It  has  been  shown  that  approximately  80%
f  smokers  who  attempt  to  quit  on  their  own  relapse  within
he  ﬁrst  month  of  abstinence  and  only  about  3--5%  remain
bstinent  at  6  months.14 This  reﬂects  the  chronic  relaps-
ng  nature  of  tobacco  dependence.  Treatment  for  smoking
essation  includes  various  methods,  from  simple  medical
dvice  to  pharmacotherapy.  Evidence-based  recommenda-
ions  indicate  that  although  counseling  and  medication  on
gia.  Published  by  Elsevier  España,  S.L.  All  rights  reserved.
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Ask
•Have you used tobacco in the last 12 months?
Yes – Current smoker: 
Take brief smoking history including number of cigarettes smoked a day, year started smoking,
presence of smoking-related disease, previous quit attempts and what happened?
Use non-judgmental questions such as “How do you feel about your smoking  at the moment?
Express concern/interest and not criticism. 
Assess: Motivation to stop:
•On a scale from 1-10 how interested are you in trying to quit?
•Are you planning to QUIT in the next 6 months?
No: Congratulate
Not planning to quit
(Precontemplation)
• Focus on motivation
Advise
• Ask, “Is there anything that
might help you
consider quitting?” or
“Can you imagine any
benefits of quitting?” 
• Offer help if the patient
should
Change his/her mind.   
Arrange
• Follow up – ask patient if
you should
discuss smoking again at
next consultation.  
5 As of smoking cessation: ask, assess, advise, assist, arrange15
Plannign to quit
Within the next 6 months
(Contemplation)
Advise
• Focus on their ambivalence,
help them motivate
themselves.
• Offer help by asking:
“What are the things you like
and don’t like about your
smoking?
“How can I help you increase
your confidence in quitting?”
Assist
• Explore barriers to
cessation.
• Offer help quitting.
• Refer to quit line or other
counselling, refer
to smoking cessation unit if
patient prefers.
• Follow up consultation or
telephone contact
within 6 months or remember
to ask when
you next see the patient.
Plannign to quit
Within the next 1 months
(Preparation/Action) 
Assist
• Provide assistance in
developing a quit plan.
• Help patient to set a quit date.
• Assist in dealing with barriers
such as fear of failure,
weight gain, social
pressure.
• Give nutritional advice:
 avoid caffeine and alcohol.
Physical activity may help.
• Assist in giving advice on
pharmacotherapy for cessation:
Withdrawal symptoms occur
 mostly during the first 2 weeks. 
Arrange
• Follow-up consultations,
phone call
-ideally weekly first
weeks, then monthly.  
1 2 3 4 5 6 7 8 9 10
Figure  1  A  guide  for  assisting  the  smoker.  The  ﬁrst  step  in  treating  tobacco  use  and  dependence  is  to  identify  tobacco
users. Asking  systematically  whether  your  patients  smoke  at  every  visit  is  imperative  (ASK).  All  smokers  should  be  advised  to
quit. This  advice  should  be  clearly  stated  and  speciﬁcally  adapted  in  relation  to  the  patient’s  problems  (ADVISE).  The  will-
ingness of  smokers  to  make  a  quit  attempt  at  this  time  should  be  assessed  (ASSESS).  If  the  patient  is  ready  to  quit,  health
care providers  should  be  prepared  to  offer  assistance.  This  entails  working  together  with  the  patient  to  set  a  sensible  plan
with a  commitment  to  a  quit  date  and  to  frequent  follow-up  visits.  Alternatively,  referring  the  patient  to  a  tobacco  interven-
tion resource  (eg,  a  smoking  cessation  quit  line  or  health  educator)  that  would  deliver  additional  treatment  to  the  patient
might be  contemplated  (ASSIST).  All  patients  who  receive  a  tobacco  dependence  intervention  should  be  regularly  assessed
for abstinence,  beginning  within  the  ﬁrst  week  after  the  quit  date.  Abstinent  patients  should  have  their  quitting  success
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heir  own  are  helpful  for  treating  tobacco  dependence  when
sed  in  combination  they  are  more  effective.13
To  help  their  patients  quit  smoking,  clinicians  can  use  the
15‘ﬁve  A’s’’  approach (Fig.  1):  ask  patients  about  smoking,
dvise  all  smokers  to  quit,  assess  willingness  to  make  a  quit
ttempt,  assist  those  who  want  to  quit,  and  arrange  follow-
p  visits  with  those  trying  to  quit.  Each  intervention  can  be
s
f
e
bompleted  in  less  than  3  min  and  has  been  associated  with
 cessation  prevalence  of  5--8%.13
There  is  a  strong  dose--response  relation  between  the
ession  length  of  person-to-person  contact  and  success-
ul  treatment  outcomes.  Intensive  interventions  are  more
ffective  than  less  intensive  interventions  and  should
e  used  whenever  possible.  Person-to-person  treatment
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delivered  for  four  or  more  sessions  appears  especially  effec-
tive  in  increasing  abstinence  rates.13
All  patients  with  ILD  should  be  routinely  asked  about  their
smoking  status.  This  advice  should  be  clearly  stated  and  per-
sonalized.  Clinicians  treating  smokers  with  ILD  have  an  ideal
‘‘teachable  moment’’  in  that  they  are  treating  a  disease
that  may  have  been  caused  or  exacerbated  by  smoking  and
that  can  be  ameliorated  by  quitting.  It  is  important  tell  the
patient  that  his  disease  is  caused  by  or  related  to  smoking
and  that  can  be  ameliorated  by  quitting.13
After  giving  this  advice,  clinicians  should  assess  whether
smokers  desire  to  quit  at  the  present  time.
For  those  smokers  ambivalent  about  quitting,  or  less
motivated,  motivational  interviewing  appear  to  be  effec-
tive  in  increasing  a  patient’s  likelihood  of  attempting  to
quit.  Therefore,  clinicians  should  use  these  techniques  to
encourage  smokers  who  are  ambivalent  about  quitting,  or
less  motivated,  to  consider  making  an  attempt.13
Clinicians  should  assist  patients  who  want  to  quit.  All
clinicians  and  clinicians-in-training  should  be  trained  in
effective  strategies  to  assist  tobacco  users  willing  to  make
a  quit  attempt  and  to  motivate  those  unwilling  to  quit.13
The  clinician  should  work  together  with  the  patient  to
set  a  date  to  quit  and  should  provide  the  patient  with
practical  advice  about  how  to  quit  and  self-help  materials.
Clinicians  should  determine  whether  the  patient  is  likely
to  require  adjunctive  help  and  whether  the  patient  is  a
candidate  for  pharmacotherapy.  Pharmacotherapy  should
be  considered  for  all  patients  motivated  to  make  a quit
attempt,  except  in  the  presence  of  speciﬁc  contraindica-
tions.  The  choice  may  take  into  account  previous  patient
experience  and  preferences.  Clinicians  should  also  present
other  treatment  options  to  their  patients  who  want  to  quit.
In  particular,  patients  should  be  made  aware  of  community
cessation  resources  available.
Clinicians  should  arrange  for  a  follow-up  visit  to  discuss
smoking  cessation  within  two  weeks  of  the  chosen  date
to  quit.13 Scheduling  follow-up  visits  (or  making  follow-up
telephone  calls)  improves  cessation  success.  More  intense
interventions  yield  better  outcomes.  Outcomes  are  inﬂu-
enced  by  a  host  of  structural  factors,  including  session
length,  session  frequency,  total  number  of  sessions,  and
number  and  types  of  treatment  modalities.13
Smokers  differ  in  their  motivation  to  quit  smoking,  and
these  differences  are  thought  to  affect  treatment  progno-
sis.  A  theoretical  structure  for  assessing  these  differences
is  offered  by  the  model  advanced  by  Prochaska  and  Di
Clemente.  Brieﬂy,  the  model  proposes  that  smokers  go
through  a  series  of  stages  (not  necessarily  linearly)  on
the  way  to  achieving  prolonged  abstinence  from  smoking
(Fig.  1):  not  thinking  seriously  about  quitting  in  the  next
six  months,  thinking  seriously  about  quitting  in  the  next  six
months,  planning  to  quit  in  the  next  month,  actually  trying
to  quit,  and  trying  to  remain  abstinent.  If  a  relapse  occurs,
smokers  should  return  to  an  earlier  stage  in  the  model.16
Helping  smokers  to  overcome  their  addiction  involves
prompting  quit  attempts  by  offering  help  to  all  smokers
without  necessarily  asking  whether  they  are  interested  in
quitting17 and  clinicians  should  use  the  motivational  inter-
viewing  on  cessation  to  encourage  all  smokers  to  quit.13
Once  established,  cigarette  smoking  is  a  very  difﬁ-
cult  addiction  to  break.  Smokers  trying  to  quit  have  to
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imultaneously  cope  with  psychological  and  pharmacolog-
cal  aspects  of  tobacco  dependence.  The  pharmacological
ffects  of  nicotine  play  a  crucial  role  in  tobacco  addic-
ion  and  therefore  pharmacotherapy  is  important  to  address
his  component  of  tobacco  dependence  in  order  to  improve
uccess  rates.  There  is  little  doubt  that  currently  mar-
eted  smoking  cessation  products  (such  as  NRT,  buproprion
nd  varenicline)  increase  the  chance  of  committed  smokers
topping  smoking,  particularly  when  combined  with  coun-
eling  programs.  This  is  because  psychological  therapies  and
ounseling  help  smokers  to  cope  with  psychological  aspects
ssociated  with  tobacco  dependence.
Unfortunately,  many  smokers  relapse  while  receiving
reatment  for  tobacco  dependence.  We  acknowledge  that
his  reﬂects  the  chronic  relapsing  nature  of  tobacco  depen-
ence  and  is  not  the  fault  of  the  physician,  nor  a  failure  of
heir  patients,  but  more  effective  smoking  cessation  inter-
entions  are  clearly  needed.
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